Voloridge Investment Management’s Tandem Diabetes Care TNDM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-230,410
Closed -$9.28M 1362
2024
Q2
$9.28M Sell
230,410
-291,222
-56% -$12.1M 0.03% 581
2024
Q1
$18.5M Sell
521,632
-430,930
-45% -$11.5M 0.07% 351
2023
Q4
$28.2M Sell
952,562
-95,401
-9% -$1.98M 0.11% 242
2023
Q3
$21.8M Buy
1,047,963
+170,932
+19% +$4.69M 0.11% 268
2023
Q2
$21.5M Buy
877,031
+392,407
+81% +$12.6M 0.1% 268
2023
Q1
$19.7M Buy
484,624
+434,770
+872% +$18M 0.1% 287
2022
Q4
$2.24M Sell
49,854
-31,905
-39% -$1.44M 0.01% 930
2022
Q3
$3.91M Buy
81,759
+20,506
+33% +$1.12M 0.02% 736
2022
Q2
$3.63M Buy
+61,253
New +$5.03M 0.02% 794
2022
Q1
Sell
-21,839
Closed -$3.29M 1701
2021
Q4
$3.29M Buy
+21,839
New +$2.95M 0.02% 882
2021
Q2
Sell
-31,491
Closed -$2.78M 1786
2021
Q1
$2.78M Buy
+31,491
New +$2.93M 0.02% 697
2019
Q2
Sell
-21,349
Closed -$1.36M 1066
2019
Q1
$1.36M Buy
+21,349
New +$1.12M 0.04% 382

Other funds holding TNDM

Voloridge Investment Management's TNDM Position: Q3 2024 in Review

Voloridge Investment Management sold out of Tandem Diabetes Care (TNDM) in Q3 2024, closing a stake of 230,410 shares — an estimated $9.28M sold.

Voloridge Investment Management first reported a position in TNDM in Q1 2019 and held it in 12 quarters. The position peaked at $28.2M in Q4 2023. 332 funds tracked by Wall St. Rank hold TNDM as of Q3 2024.

  • Voloridge Investment Management reported no remaining Tandem Diabetes Care position as of Q3 2024 after selling out during the quarter.
  • Voloridge Investment Management sold 230,410 Tandem Diabetes Care shares in Q3 2024, an estimated $9.28M.
  • Voloridge Investment Management first reported a position in Tandem Diabetes Care in Q1 2019 and held it in 12 quarters.
  • Voloridge Investment Management's Tandem Diabetes Care position peaked at $28.2M in Q4 2023.
  • 332 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q3 2024.

Based on Voloridge Investment Management's 13F filing for Q3 2024, filed 14 Nov 2024.